Recombinant Human VEGF110, premium grade, 20µg

Background
Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF) and VEGF-A, and is a member of the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family and encodes a protein that is often found as a disulfide linked homodimer. This protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. Alternatively spliced isoforms of 110,121,145,165,183,189 and 206 amino acids in length are expressed in humans.

Source
Recombinant Human VEGF110 Protein, premium grade(VE0-H5212) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 136 (Accession # NP_001165097).
Predicted N-terminus: Ala 27
It is produced under our rigorous quality control system that incorporates a comprehensive set of tests including sterility and endotoxin tests. Product performance is carefully validated and tested for compatibility for cell culture use or any other applications in the early preclinical stage. When ready to transition into later clinical phases, we also offer a custom GMP protein service that tailors to your needs. We will work with you to customize and develop a GMP-grade product in accordance with your requests that also meets the requirements for raw and ancillary materials use in cell manufacturing of cell-based therapies.

Molecular Characterization
This protein carries no "tag".
The protein has a calculated MW of 12.7 kDa. The protein migrates as 16-18 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 0.2 EU per μg by the LAL method.

Sterility
Negative

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
 
Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Detection and Quantification of VEGF Isoforms by ELISA"
Vernes, Meng
Methods Mol Biol (2015) 1332, 25-37
(2) "A new ELISA for use in a 3-ELISA system to assess concentrations of VEGF splice variants and VEGF(110) in ovarian cancer tumors"
Gutierrez, Konecny, Hong et al
Clin Chem (2008) 54 (3), 597-601
(3) "Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo"
Lowe, Araujo, Yang et al
Exp Eye Res (2007) 85 (4), 425-30
Showing 1-3 of 9 papers.